Tango Therapeutics (TNGX) Total Liabilities (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Total Liabilities of $44.3 million for Q1 2026, down 58.82% year-over-year from $107.6 million in Q1 2025, and down 15.66% quarter-over-quarter from $52.5 million in Q4 2025.
Tango Therapeutics (TNGX) Total Liabilities (2020 - 2026) Analysis & Trends
Tango Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $44.3 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 58.82% year-over-year to $44.3 million; the TTM figure through Mar 2026 stood at $44.3 million (down 58.82% YoY), while the FY2025 annual figure was $52.5 million, down 55.11% from the prior year.
- Total Liabilities for Q1 2026 stood at $44.3 million, down from $52.5 million in the prior quarter.
- The five-year high for Total Liabilities was $191.1 million in Q3 2022, with the low at $44.3 million in Q1 2026.
- The 5-year median for Total Liabilities is $141.8 million (2024), against an average of $129.2 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 2362.75% in 2022, then sank 59.35% in 2025.
- Tango Therapeutics' Total Liabilities stood at $187.0 million in 2022, then declined by 20.07% to $149.5 million in 2023, then dropped by 21.73% to $117.0 million in 2024, then tumbled by 55.11% to $52.5 million in 2025, then decreased by 15.66% to $44.3 million in 2026.
- Business Quant data shows TNGX's Total Liabilities at $44.3 million in Q1 2026, $52.5 million in Q4 2025, and $50.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 49.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.35 Mn |
| Mar 31, 2026 | 44.29 Mn |
| Dec 31, 2025 | 52.51 Mn |
| Sep 30, 2025 | 50.11 Mn |
| Jun 30, 2025 | 102.94 Mn |
| Mar 31, 2025 | 107.55 Mn |
| Dec 31, 2024 | 116.98 Mn |
| Sep 30, 2024 | 123.25 Mn |
| Jun 30, 2024 | 133.78 Mn |
| Mar 31, 2024 | 141.77 Mn |
| Dec 31, 2023 | 149.46 Mn |
| Sep 30, 2023 | 151.59 Mn |
| Jun 30, 2023 | 166.38 Mn |
| Mar 31, 2023 | 176.51 Mn |
| Dec 31, 2022 | 186.99 Mn |
| Sep 30, 2022 | 191.08 Mn |
| Jun 30, 2022 | 149.70 Mn |
| Mar 31, 2022 | 151.17 Mn |
| Dec 31, 2021 | 155.41 Mn |
| Sep 30, 2021 | 164.72 Mn |